Abstract
Background and objective
Anaemia is a major and persistent manifestation of chronic kidney disease (CKD) caused by the deficient production of erythropoietin in the kidneys, the prevalence of which is proportional to the deterioration in kidney function. Darbepoetin alfa, an erythropoiesis-stimulating protein, exhibits a lower clearance and longer terminal half-life in serum than recombinant human erythropoietin, thereby allowing for a reduced dosing frequency. A recent study in patients with CKD, using a 4-week sampling period, suggested that the terminal half-life of darbepoetin alfa in serum is longer than that reported in previous studies, which were based on a 1-week sampling period. This study was conducted to characterise the pharmacokinetic profile of a single subcutaneous dose of darbepoetin alfa 1 µg/kg in patients with CKD, using a sampling duration of 4 weeks, which was hypothesised to allow better characterisation of the terminal half-life in serum.
Methods
Twenty patients with CKD not on dialysis, with a calculated glomerular filtration rate of 20–60 mL/min and who had not been treated with erythropoietic agents in the previous 12 weeks, were enrolled into this single-dose, open-label study. Patients received a single subcutaneous dose of darbepoetin alfa (Aranesp®) 1 µg/kg on day 1, and blood samples were collected for pharmacokinetic analyses predose, 6 and 12 hours postdose and up to 28 days postdose. Seroreactivity sampling and further safety laboratory tests (clinical chemistry and urinalysis) were also performed. Patients were assessed for adverse events at each study visit. The primary endpoint was characterisation of the terminal half-life following a single subcutaneous dose of darbepoetin alfa 1 µg/kg.
Results
The mean terminal half-life in serum of darbepoetin alfa was determined to be 69.6 hours. Peak serum concentrations were reached in a median time of 36 hours postdose, and a mean apparent clearance of 3.51 mL/h/kg was comparable to that observed previously in this patient population.
Conclusion
Based on an extended sampling schedule of 4 weeks, the terminal half-life of darbepoetin alfa was approximately 70 hours. This is longer than the 48.8 hours reported previously in patients with CKD on dialysis. These data suggest that the pharmacokinetic properties of darbepoetin alfa make this erythropoietic agent well suited to an extended dosing regimen.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Kazmi WH, Kausz AT, Khan SS, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38: 803–12
Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant 2002; 17 Suppl. 11: 44–6
McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501–10
Tong EM, Nissenson AR. Erythropoietin and anemia. Semin Nephrol 2001; 21: 190–203
Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–69
Khan SS, Kazmi WH, Abichandani R, et al. Health care utilization among patients with chronic kidney disease. Kidney Int 2002; 62: 229–36
Eprex solution for injection: summary of product characteristics [product information]. High Wycombe: Janssen-Cilag Ltd, 2004
Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20: 375–81
Macdougall I. Optimizing the use of erythropoietic agents: pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17 Suppl. 5: 66–70
Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290–9
Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003; 23: 106–11
Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004; 24: 453–60
Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005; 63: 327–34
Aranesp® (darbepoetin alfa) prescribing information. Thousand Oaks (CA): Amgen Inc., 2002
Cases A. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs Today (Barc) 2003; 39: 477–95
Aranesp (darbepoetin alfa): summary of product characteristics (annex I). Thousand Oaks (CA): Amgen Inc., 2004
Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392–5
Padhi D, Jang G. Pharmacokinetics (PK) of Aranesp (darbepoetin alfa) in patients with chronic kidney disease (CKD). 42nd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress; 2005 Jun 4–7; Istanbul
Kindler J, Eckardt KU, Ehmer B, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 1989; 4: 345–9
Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 399–402
Jensen JD, Madsen JK, Jensen LW, et al. Pharmacokinetics of erythropoietin in dialysis patients before and after correction of the anaemia. Drug Invest 1994; 8: 278–87
Macdougall IC, Roberts DE, Neubert P, et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; I: 425–7
Boelaert JR, Schurgers ML, Matthys EG, et al. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1989; 9: 95–8
Petersen J, Kang MS, Hays MT. Erythropoietin can be administered during dialysis: a kinetic analysis. ASAIO J 1996; 42: 27–33
Deicher R, Horl WH. Differentiating factors between erythropoiesis-stimulating agents. Drugs 2004; 64: 499–509
Sarac E, Veres Z, Tallam S, et al. Hemoglobin responses following de novo darbepoetin alfa (ARANESP®) versus epoetin alfa (PROCRIT®) administration in anemic chronic kidney disease patients [abstract]. American Society of Nephrology 37th Annual Meeting and Scientific Exposition; 2004 29 Oct–1 Nov; St Louis (MO)
Deray G. Achieving therapeutic targets in renal anaemia: considering cost-efficacy. Curr Med Res Opin 2004; 20: 1095–101
Acknowledgements
This study was funded by Amgen Inc. All authors are employees of Amgen Inc., Thousand Oaks, CA, USA.
The authors wish to acknowledge Thomas C. Marbury, MD, Orlando Clinical Research Center, Orlando, FL, USA, and William B. Smith, MD, New Orleans Center for Clinical Research, New Orleans, LA, USA, for their assistance in conducting this study. The authors would also like to thank Donna Harrell of Amgen Inc., Thousand Oaks, CA, USA, and Gardiner-Caldwell London (Maidenhead, UK) for writing and editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Padhi, D., Ni, L., Cooke, B. et al. An Extended Terminal Half-Life for Darbepoetin Alfa. Clin Pharmacokinet 45, 503–510 (2006). https://doi.org/10.2165/00003088-200645050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200645050-00005